0001493152-22-017477.txt : 20220622 0001493152-22-017477.hdr.sgml : 20220622 20220622144856 ACCESSION NUMBER: 0001493152-22-017477 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20220616 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20220622 DATE AS OF CHANGE: 20220622 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LifeMD, Inc. CENTRAL INDEX KEY: 0000948320 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011] IRS NUMBER: 760238453 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39785 FILM NUMBER: 221031582 BUSINESS ADDRESS: STREET 1: 236 FIFTH AVENUE STREET 2: SUITE 400 CITY: NEW YORK STATE: NY ZIP: 10001 BUSINESS PHONE: (866) 351-5907 MAIL ADDRESS: STREET 1: 236 FIFTH AVENUE STREET 2: SUITE 400 CITY: NEW YORK STATE: NY ZIP: 10001 FORMER COMPANY: FORMER CONFORMED NAME: CONVERSION LABS, INC. DATE OF NAME CHANGE: 20180622 FORMER COMPANY: FORMER CONFORMED NAME: Immudyne, Inc. DATE OF NAME CHANGE: 20120514 FORMER COMPANY: FORMER CONFORMED NAME: IMMUDYNE INC DATE OF NAME CHANGE: 19950720 8-K 1 form8-k.htm
0000948320 false 0000948320 2022-06-16 2022-06-16 0000948320 LFMD:CommonStockParValue0.01PerShareMember 2022-06-16 2022-06-16 0000948320 LFMD:SeriesCumulativePerpetualPreferredStock0.0001PerShareMember 2022-06-16 2022-06-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 16, 2022

 

LIFEMD, INC.

(Exact name of Registrant as specified in its charter)

 

Delaware   001-39785   76-0238453
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

 

236 Fifth Avenue, Suite 400
New York
, NY 10001
(Address of principal executive offices, including zip code)

 

(866) 351-5907
(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.01 per share   LFMD   The Nasdaq Capital Market
Series A Cumulative Perpetual Preferred Stock, $0.0001 per share   LFMDP   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On June 16, 2022, the shareholders of LifeMD, Inc. (the “Company”) approved an amendment to the Company’s 2020 Equity and Incentive Plan (the “2020 Plan”) to increase the maximum number of shares of the Company’s common stock available for issuance under the 2020 Plan by 1,500,000 shares.

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On June 16, 2022, the Company held an annual meeting of stockholders (the “Annual Meeting”). A majority in interest of all stock issued, outstanding and entitled to vote at the Annual Meeting were present in person or by proxy, thereby constituting a quorum.

 

The matters voted upon and approved by the Company’s stockholders were:

 

  (1) The election of seven directors to serve until the next annual meeting of stockholders and until their respective successors shall have been duly elected and qualified (“Proposal 1”).
     
  (2) The approval of an amendment to the 2020 Plan to increase the maximum number of shares of the Company’s common stock available for issuance under the 2020 Plan by 1,500,000 shares (“Proposal 2”).
     
  (3) The ratification of the selection of Friedman LLP as LifeMD’s independent registered public accounting firm for the fiscal year ending December 31, 2022 (“Proposal 3”).

 

The following is a summary of the voting results for each matter presented to the shareholders:

 

Proposal 1:

 

Director’s Name   Votes For   Votes Withheld   Broker Non-Votes
Justin Schreiber   12,102,348   106,643   7,429,916
Stefan Galluppi   12,115,673   93,318   7,429,916
Naveen Bhatia   12,107,274   101,717   7,429,916
Joseph DiTrolio   10,952,820   1,256,171   7,429,916
Roberto Simon   12,023,681   185,310   7,429,916
John Strawn   10,106,178   2,102,813   7,429,916
Bertrand Velge   10,197,196   2,011,795   7,429,916

 

Proposal 2:

 

Votes For   Votes Against   Votes Abstained   Broker Non-Votes
9,513,806   2,429,175   266,010   7,429,916

 

Proposal 3:

 

Votes For   Votes Against   Votes Abstained   Broker Non-Votes
19,576,630   37,606   24,671   N/A

 

All Proposals were approved.

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    LIFEMD, INC.
       
Dated: June 22, 2022 By: /s/ Eric Yecies
     

Eric Yecies

      General Counsel and Chief Compliance Officer

 

 

 

 

EX-101.SCH 2 lfmd-20220616.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 3 lfmd-20220616_def.xml INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 4 lfmd-20220616_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Class of Stock [Axis] Common Stock, par value $0.01 per share Series A Cumulative Perpetual Preferred Stock, $0.0001 per share Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 lfmd-20220616_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Cover
Jun. 16, 2022
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 16, 2022
Entity File Number 001-39785
Entity Registrant Name LIFEMD, INC.
Entity Central Index Key 0000948320
Entity Tax Identification Number 76-0238453
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 236 Fifth Avenue
Entity Address, Address Line Two Suite 400
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10001
City Area Code 866
Local Phone Number 351-5907
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock, par value $0.01 per share  
Title of 12(b) Security Common Stock, par value $0.01 per share
Trading Symbol LFMD
Security Exchange Name NASDAQ
Series A Cumulative Perpetual Preferred Stock, $0.0001 per share  
Title of 12(b) Security Series A Cumulative Perpetual Preferred Stock, $0.0001 per share
Trading Symbol LFMDP
Security Exchange Name NASDAQ
XML 7 form8-k_htm.xml IDEA: XBRL DOCUMENT 0000948320 2022-06-16 2022-06-16 0000948320 LFMD:CommonStockParValue0.01PerShareMember 2022-06-16 2022-06-16 0000948320 LFMD:SeriesCumulativePerpetualPreferredStock0.0001PerShareMember 2022-06-16 2022-06-16 iso4217:USD shares iso4217:USD shares 0000948320 false 8-K 2022-06-16 LIFEMD, INC. DE 001-39785 76-0238453 236 Fifth Avenue Suite 400 New York NY 10001 866 351-5907 false false false false Common Stock, par value $0.01 per share LFMD NASDAQ Series A Cumulative Perpetual Preferred Stock, $0.0001 per share LFMDP NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 3 23 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://lifemd.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm lfmd-20220616.xsd lfmd-20220616_def.xml lfmd-20220616_lab.xml lfmd-20220616_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 3, "dts": { "definitionLink": { "local": [ "lfmd-20220616_def.xml" ] }, "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "lfmd-20220616_lab.xml" ] }, "presentationLink": { "local": [ "lfmd-20220616_pre.xml" ] }, "schema": { "local": [ "lfmd-20220616.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 65, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 2, "memberStandard": 0, "nsprefix": "LFMD", "nsuri": "http://lifemd.com/20220616", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-06-16to2022-06-16", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://lifemd.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-06-16to2022-06-16", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "LFMD_CommonStockParValue0.01PerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock, par value $0.01 per share" } } }, "localname": "CommonStockParValue0.01PerShareMember", "nsuri": "http://lifemd.com/20220616", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "domainItemType" }, "LFMD_SeriesCumulativePerpetualPreferredStock0.0001PerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series A Cumulative Perpetual Preferred Stock, $0.0001 per share" } } }, "localname": "SeriesCumulativePerpetualPreferredStock0.0001PerShareMember", "nsuri": "http://lifemd.com/20220616", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://lifemd.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 14 0001493152-22-017477-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-017477-xbrl.zip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end